Showing results (1-10 of 262) with videos related to
Sort By:
Pageof 27
Nature Reviews. Immunology|November 30, 2018
Statins: a viable candidate for host-directed therapy against infectious diseasesSuraj P Parihar, Reto Guler, Frank BrombacherScientific Reports|September 17, 2016
Topical Simvastatin as Host-Directed Therapy against Severity of Cutaneous Leishmaniasis in MiceSuraj P Parihar, Mary-Anne Hartley, Ramona Hurdayal, et al.Vaccine|November 25, 2010
Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in miceReto Guler, Suraj P Parihar, Gunther Spohn, et al.Frontiers in Immunology|November 8, 2021
Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for TuberculosisReto Guler, Mumin Ozturk, Solima Sabeel, et al.Plos One|October 3, 2013
Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escapeSuraj P Parihar, Reto Guler, Dirk M Lang, et al.European Journal of Immunology|February 3, 2011
PKCδ regulates IL-12p40/p70 production by macrophages and dendritic cells, driving a type 1 healer phenotype in cutaneous leishmaniasisReto Guler, Mona Afshar, Berenice Arendse, et al.The Journal of Infectious Diseases|October 18, 2013
Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturationSuraj P Parihar, Reto Guler, Rethabile Khutlang, et al.Oncotarget|September 18, 2015
Targeting Batf2 for infectious diseases and cancerReto Guler, Sugata Roy, Harukazu Suzuki, et al.Plos One|March 20, 2015
IL-4Rα-dependent alternative activation of macrophages is not decisive for Mycobacterium tuberculosis pathology and bacterial burden in miceReto Guler, Suraj P Parihar, Suzana Savvi, et al.Frontiers in Immunology|July 5, 2021
IL-4-Responsive B Cells Are Detrimental During Chronic Tuberculosis Infection in MiceSuraj P Parihar, Mumin Ozturk, Maxine A Höft, et al.Pageof 27